Compugen: Earnings Quality and the Gap Between Deferred Revenue, Phase 1, and Cash
Compugen recognized $7.8 million of Gilead revenue in 2025, but most of the cash behind that line arrived in 2024. That matters because the remaining $35.9 million of deferred revenue can still support future accounting revenue without creating fresh cash at the same pace.
Where the line between earnings and cash really sits
The main article argued that 2025 bought Compugen time, not proof. This follow-up isolates the line item that is easiest to misread: the Gilead revenue. On the surface, it looks like another sign that the company can generate revenue while still operating as a clinical-stage biotech. In practice, it is mostly a reminder that reported revenue, deferred revenue and fresh cash are three different things.
This is the core point. In 2025, Compugen recognized $7.764 million of Phase 1 revenue under the Gilead agreement. But that line did not come from a new payment received in 2025. It came from work performed against a contractual obligation that had already been largely funded by the $60 million upfront payment and the $30 million IND milestone payment received in 2024.
That is also why deferred revenue remains central to the story. When a biotech reports profit, the right question is not only how much revenue was recognized, but also which pocket it came from: new cash, the release of a prior contract liability, or a mix of both. In Compugen’s 2025 filing, part of the answer is already spelled out in the balance sheet and the cash flow statement.
| Number | What it says | What it does not say |
|---|---|---|
| $7.764 million | Phase 1 revenue recognized from Gilead in 2025 | A new customer payment received in 2025 |
| $35.913 million | Deferred revenue and remaining performance obligations at year-end 2025 | Free cash already available without further performance |
| $31.634 million | 2025 operating cash flow | Proof that Gilead refilled the cash story with fresh 2025 money |
What was actually sold to Gilead, and when it was recognized
The importance of the Gilead agreement is not just its headline size. It is its accounting structure. Compugen does not describe one single promise here. It breaks the agreement into three separate obligations: the GS-0321 license, the IND-related activities, and the Phase 1 research and development activities. The license itself was treated as functional intellectual property with standalone utility, so the amount allocated to that piece was recognized back in 2023, when the IP was made available to Gilead. The IND and Phase 1 components, by contrast, are recognized over time.
That split matters because it means the 2025 line is not a mechanical tail from the upfront payment. It is a very specific execution line inside the agreement: Phase 1 work. The company uses an input method here, which means revenue is recognized based on actual internal and external costs incurred relative to the total cost expected to complete the Phase 1 obligation.
Put differently, 2025 does not tell us that Gilead paid again. It tells us that Compugen completed more work and therefore earned the right to move another slice of previously booked consideration from the balance sheet into the income statement.
That chart sharpens how concentrated 2025 really was. Out of total revenue of $72.764 million, $65 million came from the AstraZeneca amendment, and $7.764 million came from Phase 1 services for Gilead. There is no broader operating revenue engine quietly emerging underneath.
| Gilead contract component | Recognition pattern | Why it matters for 2025 |
|---|---|---|
| GS-0321 license | Point in time, when the IP was made available | Not the main source of 2025 revenue |
| IND activities | Over time | Mostly a 2024 accounting story |
| Phase 1 activities | Over time, based on actual cost versus total expected cost | This is the exact $7.764 million line in 2025 |
Deferred revenue did not disappear, it just moved upstairs
This is where the filing becomes especially clear. At the end of 2024, deferred revenue stood at $43.677 million. In 2025, the company recognized $7.764 million as Phase 1 revenue. At the end of 2025, deferred revenue still stood at $10.970 million in current liabilities and $24.943 million in non-current liabilities, or $35.913 million in total.
That is not just a clean sequence of numbers. It shows, almost one for one, what happened: part of the amount that had been sitting on the balance sheet as a contract liability moved into the income statement, without requiring a new collection event in that same year. The filing says this explicitly: of the $43.677 million of deferred revenue recorded at the end of 2024, $7.764 million was recognized as revenue during 2025.
This is also where many readers miss the real implication. Deferred revenue is not a technical footnote. It is a reservoir of future accounting revenue that has already been largely funded in advance. At the end of 2025, the company says it still had $35.913 million of transaction price allocated to remaining performance obligations, and that it expects to recognize 31% of that amount over the next 12 months, with the remainder recognized through 2029.
So even if no new milestone cash arrives tomorrow, future income can still show up in the financial statements. That is not a problem, and it is not an accounting gimmick. It is simply why reading Compugen through the revenue line alone can overstate the pace at which new cash is being created in real time.
Why the auditors flagged Phase 1 in particular
The auditors singled out Phase 1 revenue recognition under the Gilead agreement as a critical audit matter. That does not mean they are challenging the contract itself. It does mean this is where judgment becomes especially heavy. The reason is straightforward: the revenue is not recognized off a fixed calendar date or a hard milestone. It is recognized off an estimated measure of progress.
That progress is measured through costs already incurred versus the total costs expected to complete the obligation. As a result, any change in expected direct labor or third-party costs can shift revenue across periods. If the total expected cost rises, the completion percentage falls and revenue recognition stretches out. If the expected cost tightens, some revenue can move forward.
That is not an accusation. It is a reading discipline. The $7.764 million recognized in 2025 is not “hard” in the same way as the $65 million AstraZeneca upfront payment that landed in cash. It is revenue derived from a progress model, so its quality depends partly on the quality of the estimate.
The filing also makes clear that Compugen still bears the cost of the Phase 1 trial, including GS-0321 drug supply, while Gilead provides zimberelimab for the trial. That reinforces the point that this is an execution line, not a passive royalty or a pure license tail. There is real work underneath it, real cost underneath it, and revenue recognized according to the completion of that work.
What cash flow says, and what it does not
The cleanest way to see the earnings-versus-cash gap is through the cash flow statement. Under operating adjustments, the filing shows a $7.764 million decrease in deferred revenues. That is exactly the amount recognized as Phase 1 revenue. In other words, the filing itself marks that part of reported earnings came from consuming a prior contract liability rather than from collecting new customer cash in the year.
That does not conflict with the fact that operating cash flow was positive at $31.634 million. But it does explain where that cash flow came from. Management states that the decline in operating cash flow in 2025 versus 2024 was mainly due to the $65 million upfront payment collected from AstraZeneca in 2025, compared with $91.5 million collected in 2024 from Gilead and AstraZeneca, net of withholding taxes, offset by cash-based operating expenses.
The implication is clear. 2025 was not a year in which Gilead turned the cash tap back on. The large Gilead cash inflows came earlier, through the $60 million upfront payment received in January 2024 and the $30 million IND milestone received in 2024, with 15% withholding tax applied in both cases. In 2025, the Gilead story ran mainly through the income statement and through the decline in deferred revenue.
That is why positive 2025 cash flow does not turn Gilead into fresh 2025 funding. It simply shows that the company was able to combine cash received earlier, the AstraZeneca upfront payment, and ongoing clinical execution that allows revenue to be recognized over time.
Conclusion
The right way to read Gilead in 2025 is not as a new operating revenue engine. It is as an earnings-quality test. On one hand, Compugen did perform real Phase 1 work, so it is legitimate to move part of the consideration into revenue. On the other hand, that is not proof that new cash entered at the same pace, and it is not proof of a repeatable revenue base that can be projected forward without caution.
The thesis in one line: Gilead improved reported 2025 earnings, but it did so mainly by releasing deferred revenue as Phase 1 progressed, not by creating new cash in that same year.
That also defines the checklist for the next filings. Readers should spend less time on the revenue headline and more time on three things: the pace at which deferred revenue keeps unwinding, changes in Phase 1 cost estimates, and whether a new event appears that brings in additional cash or pushes GS-0321 into a deeper level of Gilead commitment. Until then, part of Compugen’s future revenue already sits on the balance sheet, not in new cash flow.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.